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Since the discovery of the Nobel prize-winning mechanism of RNA interference (RNAi) ten
years ago, it has become a promising drug target for the treatment of multiple diseases,
including cancer. There have already been some successful applications of siRNA drugs in
the treatment of age-related macular degeneration and respiratory syncytial virus infec-
tion. However, significant barriers still exist on the road to clinical applications of siRNA
drugs, including poor cellular uptake, instability under physiological conditions, off-target
effects and possible immunogenicity. The successful application of siRNA for cancer
therapy requires the development of clinically suitable, safe and effective drug delivery
systems. Herein, we review the design criteria for siRNA delivery systems and potential
siRNA drug delivery systems for cancer therapy, including chemical modifications, lipid-
based nanovectors, polymer-mediated delivery systems, conjugate delivery systems, and
others.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
RNA interference (RNAi) was first discovered in plants, but it
was not widely noted in animals until Fire and Mello
demonstrated that double-stranded RNA (dsRNA) can cause
greater suppression of gene expression than single-stranded
RNA (ssRNA) in Caenorhabditis elegans [1]. Due to the excel-
lent gene silencing potential of RNAi, it has attracted broad
attention in terms of how to harness the capabilities of RNAi.
In 2001, Tuschl et al. first transferred dsRNA into mammalian
cells and solved the interferon effect of dsRNA transfection in3600402.
ang).
g Pharmaceutical Univer
University. Production anthese cells, which broadened the therapeutic use of Rania [2].
In 2010, Davis et al. reported the first targeted siRNA delivery
nanoparticle in humans via systemic injection, which pro-
vided a reference and a solid foundation for siRNA clinical use
[3]. In recent years, RNAi has become more and more impor-
tant in gene silencing and drug development because of its
high specificity, significant effect, minor side effects and ease
of synthesis.
Naturally, RNAi is an important defense mechanism by
which eukaryotic cells can degrade exogenous genes, like
viruses. When dsRNA enters the cell, it is first cleaved into
short double stranded fragments of ~20 nucleotide siRNAs bysity.
d hosting by Elsevier B.V. All rights reserved.
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into the passenger strand and the guide strand. After that, the
guide strand is incorporated into the RNA-induced silencing
complex (RISC), while the passenger strand is degraded. In
the RISC, the guide strand of siRNA pairs with a comple-
mentary sequence in a messenger RNAmolecule and induces
cleavage by Argonaute, which causes post-transcriptional
gene silencing. There are three strategies for RNAi: short
hairpin RNA (shRNA), endogenous microRNA (miRNA) and
small interfering RNA (siRNA). siRNA is more suitable for drug
use because it does not require genome integration and can
be easily synthesized. Since rational design of siRNA can
specifically inhibit endogenous and heterologous gene
expression, it can modulate any disease-related gene
expression. For example, most cancer is caused by oncogene
overexpression or gene mutation, so it may be possible to
cure cancer by disease-related gene suppression via rational
siRNA design. Owing to its great potential in biological
research and drug development, RNAi was awarded the Nobel
Prize for medicine in 2006. Since then, billions of dollars have
been invested in the therapeutic application of RNAi in
humans. At least 22 RNAi-based drugs have entered clinical
trials (Table 1).
Among these clinical trials, most siRNAs were adminis-
tered by local delivery, typically via the intravitreal or intra-
nasal routes. However, local delivery may not be appropriate
for all diseases. Under some circumstances, systemic drug
administration by intravenous (i.v.) injection is needed, and
delivery systems will be necessary to administer the siRNA
payload. For example, PRO-040201 (ApoB-SNALP) adminis-
trated by i.v. injection was developed by Tekmira with a stable
nucleic acid lipid particle (SNALP) system. It was developed for
the treatment of hypercholesterolemia by targeting ApoB,
which is produced by hepatocytes. In July 2009, Tekmira
initiated a Phase I clinical trial for PRO-040201. Seventeen
subjects received a single dose at one of seven different dosing
levels and six subjects received a placebo. The results revealed
that ApoB siRNA was delivered into hepatocytes efficiently
and resulted in a significant reduction of LDL and triglycerides
in blood. However, Tekmira terminated the clinical trial in
January 2010 because one of the two subjects treated with the
highest dose experienced flu-like symptoms consistent with
stimulation of the immune system caused by the ApoB siRNA
payload [4]. Calando Pharmaceuticals (Pasadena, California,
USA) has developed an siRNA therapeutic (CALAA-01), which
is a cyclodextrin-based polymeric nanoparticle containing the
M2 subunit of ribonucleotide reductase (RRM2) targeted
siRNA. CALAA-01 was modified with the human transferrin
(TF) protein and polyethylene glycol (PEG) to improve its sta-
bility [3]. Unfortunately, its phase I clinical trial has been
terminated in 2013 according to U.S. Food and Drug Admin-
istration (FDA). In addition to the abovementioned siRNA
drugs, many more are in the developmental pipeline.2. Advantages of siRNA and barriers to
siRNA in cancer therapeutics
Compared to chemotherapeutic anti-cancer drugs, there are a
lot of advantages of siRNAdrug. Due to the specialmechanismof siRNA, it has four advantages as a potential cancer thera-
peutic strategy. The first is its high degree of safety. siRNA acts
on the post-translational stage of gene expression, so it does
not interact with DNA and thereby avoids the mutation and
teratogenicity risks of gene therapy. The second advantage of
siRNA is its high efficacy. In a single cancer cell, siRNA can
cause dramatic suppression of gene expression with just
several copies. Compared to other small molecule drugs or
antibody-based drugs, the greatest advantages of siRNA are
the unrestricted choice of targets and specificity determined
by the principle of complementary base pairing. This strategy
also benefits from rapid developments in molecular biology
and whole-genome sequencing. In addition, comprehensive
nucleotide sequence databases have been established,
including human genomic databases, cDNA databases and
disease gene databases, which have laid a solid foundation for
siRNA drug development. The basic strategy of an siRNA drug
is to treat cancer by silencing the specific cancer-promoting
gene with rationally designed siRNA. Of course, it is also
possible to design effective siRNA drug targeting for any dis-
ease gene according to the mRNA sequence.
However, several barriers still exist on the road to siRNA
clinical use for cancer therapy (Fig. 1). Firstly, siRNA is un-
stable under physiological conditions. When siRNA traffics
through the blood, it is easily digested by nucleases in the
serum. The intracellular trafficking of siRNA delivered by
different reagents generally begins in early endosomes. These
early endosomes subsequently fuse with sorting endosomes,
which in turn transfer their contents into late endosomes. The
endosomal compartments of cell are significantly acidic (pH
5.0~6.2), while the cytosol or intracellular space is neutral
(pH z 7.4) [5]. Endosome is then relocated to the lysosomes,
which are further acidified (pH z 4.5) and contain various
nucleases that promote the degradation of siRNA [6]. The ideal
administration route of siRNA is systemic injection, so that
siRNA can reach cancer cells more efficiently. After injection
into the blood, siRNA is easily enzymatically degraded by
endogenous nucleases, filtered by the kidney, taken up by
phagocytes and aggregatedwith serumproteins [7]. One of the
first biological barriers encountered by administered siRNA is
the nuclease activity in plasma and tissues. The major
nuclease in plasma is a 30 exonuclease; however, cleavage of
internucleotide bonds can also take place. The reported half-
life for unmodified siRNA in serum ranges from several mi-
nutes to 1 h [8]. In addition, the kidney plays a key role in
siRNA clearance; several studies in animals have reported that
the biodistribution of siRNA shows the highest uptake in the
kidney [9]. In addition to circulating nuclease degradation and
renal clearance, a major barrier to in vivo delivery of siRNA is
uptake by the reticuloendothelial system (RES). The RES is
composed of phagocytic cells, including circulating mono-
cytes and tissue macrophages, the physiological function of
which is to clear foreign pathogens and to remove cellular
debris and apoptotic cells [10]. Tissue macrophages are most
abundant in the liver (where they are called Kupffer cells) and
the spleen, tissues that also receive high blood flow and
exhibit a fenestrated vasculature. Thus, it is not surprising
that these organs accumulate high concentrations of siRNA
following systemic administration. siRNA uptake after stan-
dard i.v. tail vein injection or intraperitoneal (i.p.) injection
Table 1 e RNAi based drugs in clinical trials.
Drug Target Delivery
system
Administration route Disease Phase Company ClinicalTrials.gov
identifier
TD101 K6a(N171K
mutation)
Naked siRNA Foot-pat injection Pachyonychia Congenita I Pachyonychia Congenita
Project
NCT00716014
AGN211745 VEGFR1 Naked siRNA Single intravitreal injection Age-Related Macular Degeneration,
Choroidal Neovascularization
II Allergan NCT00363714
QPI-1007 CASP2 Naked siRNA Single intravitreal injection Optic Atrophy Non-arteritic Anterior
Ischemic Optic Neuropathy
I Quark Pharmaceuticals NCT01064505
Bevasiranib VEGF Naked siRNA Single intravitreal injection Diabetic Macular Edema II Opko Health, Inc. NCT00306904
SYL1001 TRPV1 Naked siRNA Ocular topical
administration
Ocular Pain, Dry Eye Syndrome I, II Sylentis, S.A. NCT01776658
I5NP p53 Naked siRNA Intravenous injection Injury of Kidney, Acute Renal Failure I Quark Pharmaceuticals NCT00554359
SYL040012 ADRB2 Naked siRNA Ophthalmic-drop
administration
Glaucoma, Ocular Hypertension I, II Sylentis, S.A. NCT01227291
ALN-RSV01 RSV
nucleocapsid
Naked siRNA Nebulization
administration
Respiratory syncytial virus
infections
II Alnylam Pharmaceuticals NCT00658086
PF-655 RTP801 Naked siRNA Single intravitreal injection Choroidal neovascularization,
diabetic retinopathy, diabetic
macular edema
II Quark Pharmaceuticals NCT01445899
siRNA-EphA2-DOPC EphA2 LNP Intravenous injection Advanced Cancers I M.D. Anderson Cancer
Center
NCT01591356
Atu027 PKN3 LNP Intravenous injection Advanced Solid Tumors I Silence Therapeutics GmbH NCT00938574
PRO-040201 ApoB LNP Intravenous injection Hypercholesterolemia I Tekmira Pharmaceuticals
Corporation
NCT00927459
TKM-080301 PLK1 LNP Hepatic intra-arterial
administration
Multiple Cancers I National Cancer Institute
(NCI)
NCT01437007
ALN-VSP02 KSP and VEGF LNP Intravenous injection Solid tumors I Alnylam Pharmaceuticals NCT01158079
TKM-100201 VP24, VP35, Zaire
Ebola L-
polymerase
LNP Intravenous injection Ebola-virus infection I Tekmira Pharmaceuticals NCT01518881
ALN-PCS02 PCSK9 LNP Intravenous injection Hypercholesterolemia I Alnylam Pharmaceuticals NCT01437059
ALN-TTR02 TTR LNP Intravenous injection Transthyretin-mediated amyloidosis II Alnylam Pharmaceuticals NCT01617967
CALAA-01 RRM2 Cyclodextrin NP Intravenous injection Cancer Solid Tumor I Calando Pharmaceuticals NCT00689065
siG12D LODER KRAS LODER polymer Intratumoral
administration
Pancreatic Ductal Adenocarcinoma
Pancreatic Cance
I Silenseed Ltd NCT01188785
RXi-109 CTGF Self-delivering
RNAi compound
Multiple intradermal
administrations
Cicatrix scar prevention I RXi Pharmaceuticals NCT01780077
ALNeTTRsc TTR siRNAeGalNAc
conjugate
Subcutaneous injection Transthyretin-mediated amyloidosis I Alnylam Pharmaceuticals NCT01814839
ARC-520 Conserved
regions of HBV
DPC Intravenous injection HBV I Arrowhead Research NCT01872065
LNP, lipid nanoparticle; NP, nanoparticle; DPC, dynamic polyconjugate; VEGFR1, vascular endothelial growth factor receptor 1; CASP2, Caspase 2; TRPV1, transient receptor potential cation channel,
subfamily V, member 1; PKN3, protein kinase N3; ApoB, apolipoprotein B; PLK1, polo-like kinase 1; PCSK9, Proprotein convertase subtilisin/kexin type 9; TTR, transthyretin; RRM2, ribonucleotide
reductase M2; CTGF, connective tissue growth factor; HBV, hepatitis B virus.
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Fig. 1 e Barriers encountered by siRNA following systemic administration. siRNA may be degraded in the blood or removed
by renal excretion or macrophages. siRNAs may not reach their target cells because of electrostatic repulsion. Once
internalized, siRNAs may be prevented from reaching their intracellular targeted mRNA by an inability to escape from the
endosomeelysosome pathway.
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 1e1 24has been noted in the liver, spleen, kidney and bone marrow
at 4 h, but the overall signal was weak [11].
Secondly, free siRNA, which is a type of anionic and hy-
drophilic double-stranded small RNA, is not readily taken up
by cells. Moreover, the hydrophilicity and negative charge of
siRNA molecules prevents them from readily crossing bio-
logical membranes. Therefore, siRNA needs to be packaged in
vesicles in order to enter cells.
The third barrier is the off-target effects of siRNA, which
lead to unanticipated phenotypes that complicate the inter-
pretation of the therapeutic benefits of siRNA, including
siRNA-induced sequence-dependent regulation of unin-
tended transcripts through partial sequence complementarity
to their 30 UTRs, as well as widespread effects on miRNA
processing and function through saturation of the endoge-
nous RNAi machinery by exogenous siRNA [12]. The scale of
off-target effects was found to be remarkable during the
identification of novel components of signal transduction
pathways by RNAi screens [13]. All siRNA hits, whatever their
intended direct target, reduced themRNA levels of two known
upstream pathway components, TGF-b receptor 1 and 2
(TGFBR1 and TGFBR2), via miRNA-like off-target effects [13].
Transfection of small RNAs can globally perturb gene regula-
tion by endogenousmiRNA. Targets of endogenousmiRNA are
expressed at significantly higher levels after specific siRNA
transfection, consistent with the impaired effectiveness of
endogenous miRNA repression, which results in unexpected
changes in gene expression.
Lastly, siRNA is not as safe as expected. High levels of
siRNA have been known to result in the activation of innate
immune responses and the production of cytokines in vitro
and in vivo [14,15]. Mammalian immune cells express a sub-
family of pattern-recognition receptors called Toll-like re-
ceptors (TLRs) that recognize pathogen-associated molecular
patterns, including unmethylated CpG DNA and viral dsRNA[12]. Several TLRs are involved in the recognition of siRNA,
including TLR3, TLR7 and TLR8 [16,17]. TLR3 is the receptor for
dsRNA, and cultured human embryonic kidney HEK-293 cells
overexpressing TLR3 are capable of recognizing siRNA. siRNA
has been shown to activate TLR3 signaling in a sequence-
independent manner [16]. TLR7 and TLR8 were initially
shown to mediate the recognition of RNA viruses and small
synthetic antiviral compounds referred to as imidazoquino-
lines [18]. It has been shown that TLR7 is absolutely required
for the induction of cytokines using the appropriate knockout
mice in murine immune cells in response to siRNA [14,15].
siRNA can be recognized by human plasmacytoid dendritic
cells (pDCs) through TLR7 and by humanmonocytes, likely via
TLR8 [19]. TLR7 and TLR8mediate the recognition of siRNA in a
sequence-dependent manner, and RNA sequences, including
UG dinucleotides and the 50-UGU-30 motif, are preferentially
recognized [18]. Thus, the sequence issue of siRNA-mediated
immune stimulation requires further investigation.
In consideration of these barriers to realizing the broad
potential of siRNA-based therapeutics, safe and effective
siRNA delivery methods are desired. Therefore, chemical
modifications and/or delivery methods are required to bring
siRNA to its site of action without adverse effects. A broad
diversity of materials is under exploration to address the
challenges of in vivo delivery, including polymers, lipids,
peptides, antibodies, aptamers, and small molecules. Suc-
cessful systems have been developed by rational design or
discovered using high-throughput screens.3. The design criteria of an siRNA delivery
system for cancer therapy
To apply siRNA into cancer therapy, the delivery barriers of
siRNA in vivo are the predominant problems to be solved.
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therapy, there are several criteria for siRNA delivery system.
As siRNAmolecules are too large (~13 kDa) and too negatively
charged to diffuse across cancer cell membranes alone, the
issue of effective and non-toxic delivery is a key challenge and
serves as the most significant barrier between siRNA tech-
nology and its therapeutic application [20]. To administer
siRNA systemically and allow it to cross physiological barriers
to reach its site of action, delivery systemsmust be engineered
to (I) provide serum stability, (II) allow immune evasion, (III)
mitigate interactions with serum proteins and non-cancer
cells, (IV) resist renal clearance, (V) enhance vascular perme-
ability to reach cancer tissues, (VI) permit cell entry and en-
dosome escape to enter the RNAi machinery [7,20] and (VII)
have low toxicity.
Firstly, siRNA should be injected into blood for cancer
therapy. As soon as naked RNAmolecules are administered to
the blood, the innate immune system is stimulated and serum
nucleases immediately degrade the RNA. A common strategy
to avoid these problems is to modify the siRNA backbone
through chemical elements. The most frequently used stra-
tegies of chemical modification are incorporation of 20-O-
methyl and 20-deoxy-20-fluoro groups, locked or unlocked
nucleic acids, or phosphorothioate linkages [21]. Special
design of siRNA sequence and structure can also avoid
recognition by the innate immune system. Although chemical
modifications can solve some problems of siRNA delivery,
nanoparticles that encapsulate siRNA are better at protecting
it from degradation and immune recognition [22]. So, not only
modifications of the siRNA chemical structure are needed, but
additional delivery materials are also necessary to surmount
other barriers in the body.
There are many components in the blood that will interact
with siRNA delivery in various ways. High positive charges on
the surface of nanoparticles can cause unfavorable aggrega-
tion with erythrocytes [23], but this kind of interaction be-
tween nanoparticles and serum proteins can also aid uptake
by cancer cells [24,25]. For example, many liposomal delivery
systems, as well as siRNA conjugated to lipophilic molecules,
interact with serum lipoproteins and subsequently gain entry
into hepatocytes that take up those lipoproteins [24]. Howev-
er, serum opsonin proteins can also be adsorbed on the sur-
face of delivery nanoparticles, and tag them for uptake by the
mononuclear phagocyte system (MPS) [7,26]. The main
pathway by which nanoparticles are cleared from the blood is
opsonization and subsequent uptake by the MPS, which pre-
vents them from reaching their targets. The most commonly
used and best characterized strategy to minimize interaction
between delivery nanoparticles and serum proteins is
shielding the nanoparticle surface with polyethylene glycol
(PEG) [7,27]. Rational PEGylation of delivery nanoparticles can
prolong blood circulation time by minimizing non-specific
interactions of nanoparticles with serum proteins, the
innate immune system and other non-target tissues. PEG
forms a barrier around nanoparticles that provides steric
stabilization and protection from the physiological sur-
roundings [28]. The length of the PEG chain can have a sig-
nificant influence on its stabilization and protective
properties, and chain length is typically optimized for each
individual delivery system.After systemic administration, there are many ways by
which siRNA leaves the bloodstream, including through the
liver, spleen, kidney and lung. However, kidney clearance is
the most common pathway. The kidney is composed of many
glomeruli, which work as a natural filtration barrier that al-
lows water and small molecules to pass into nascent urine
while larger molecules are retained in the circulation [29]. The
pore size of the glomerular filtration barrier is roughly 8 nm
[30], and excretion through the kidney typically occurs for
molecules less than 50 kDa in size [31]; the molecular weight
of naked siRNA is about 13 kDa [20]. Therefore, siRNA passes
through glomeruli and flow into the urine. By complexing
siRNA with synthetic materials, the size of the delivery
nanoparticle can be increased to avoid glomerular filtration
through the kidneys and reserve the siRNA for alternative
organ targets [31]. Many delivery systems are designed to be
larger than 20 nm [32]. However, 20 nm is a strict limit as
dynamic polyconjugates (DPCs; 10 nm) [33] and triantennary
N-acetylgalactosamine (GalNAc) conjugates are both highly
effective delivery systems.
Based on the enhanced permeability and retention effect
(EPR effect), which means that nanoparticles ranging in size
from tens to hundreds of nanometers are passively accumu-
lated in tumors to a greater extent than in normal tissue,
mainly because newly formed tumor vessels are usually
abnormal in form and architecture, many nanosized drug
delivery systems have been developed including micelles or
vesicles, dendrimers, liposomes and inorganic hybrid parti-
cles for cancer therapy.
Most siRNA delivery systems undergo cellular internali-
zation through endocytosis. Various delivery systems aim to
improve the rate of cellular uptake by incorporating targeting
ligands that bind specifically to receptors on target cells to
induce receptor-mediated endocytosis [34]. Adsorption of
serum proteins on the nanoparticle surface may hinder this
ligandereceptor interaction [35]. Other systems use cell-
penetrating peptides that can induce cell uptake through
endocytosis or non-endocytic mechanisms [36]. Endocytosed
materials are taken up into membrane-bound endocytic ves-
icles, which fuse with early endosomes and become increas-
ingly acidic as they mature into late endosomes. Some
delivery systems incorporate materials that are designed to
respond to a low pH environment by becoming membrane-
disruptive in order to trigger the release of siRNA from endo-
somes into the cytoplasm [33,37]. Still, the exact endosomal
release mechanism of many siRNA delivery systems is poorly
understood.
Additionally, low toxicity is the most important part of
siRNA delivery systems. If siRNA delivery provokes unac-
ceptable toxicity on either a cellular or systemic level, even the
most efficacious siRNA delivery system will be rendered use-
less. Viral vectors, which were among the first vehicles to be
studied for siRNA delivery, can induce unacceptable levels of
toxicity through the activation of immune responses [38].
Therefore, synthetic lipids and polymers have been developed
to offer alternatives to viral vectors for nucleic acid delivery
applications, and are carefully formulated to avoid stimula-
tion of the immune system [15]. Clearance of larger molecular
mass materials typically requires them to be biodegradable.
The use of biodegradable, high molecular mass polycations
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the cell can help reduce cytotoxicity [39].4. Potential siRNA drug delivery systems for
cancer therapy
Although many strategies that can deliver siRNA into the
cytoplasm of cancer cells have been reported, most of them
can only satisfy in vitro applications. The majority of siRNA
drugs in clinical trials are directly administered to pathology-
bearing regions to avoid the complexity of systemic delivery.
They can be divided into nine classes according to their tar-
gets, including eye diseases, pachyonychia congenita, viral
diseases, asthma, hypercholesterolemia, acute kidney injury,
thyroxine amyloidosis, and cancer [40]. However, the excel-
lent therapeutic potential of siRNA for cancer therapy remains
uncovered. It is necessary to introduce systemic routes of
siRNA delivery to treat most cancers.
As mentioned above, the design criteria of an in vivo, sys-
temic siRNA delivery system should include biocompatibility,
biodegradability, and non-immunogenicity. Additionally, the
system should protect siRNA from serum nucleases and
deliver it into target cells efficiently. Finally, the delivery sys-
tem should provide siRNA an endosome escape ability to enter
the RNAi machinery and activate RNAi pathways [41,42]. The
currently developed siRNA delivery systems for cancer ther-
apy can be divided into four categories: chemical modifica-
tions, lipid-based nanovectors, polymer-mediated delivery
systems, conjugate delivery systems, and others (exosomes,
RNAi-microsponges, oligonucleotide nanoparticles).
4.1. Chemical modifications of anti-cancer siRNA
Although chemical modifications do not provide a carrier for
siRNA, they show great potential and are necessary in cancer
therapeutic siRNA delivery systems. With rational chemical
modifications, siRNA can acquire advantages such as serum
stability, immune escape ability, and RNAi machinery access
[8,43,44].
Chemical modifications can be introduced at the 50 or 30-
terminus, backbone, sugar or nucleobase of siRNA. The most
common modification site of siRNA is the 20 position of the
ribose ring, which has been proven to enhance siRNA stability
by preventing degradation by endonucleases. The two modi-
fication strategies, i.e. 20-O-methyl and 20-deoxy-20-fluoro, are
quite well-understood and commercialized, and have been
shown to enhance the serum stability of siRNA and increase
its in vivo potential. Some other approaches also exist, such as
replacement of the phosphodiester (PO4) group with phos-
phothioate (PS) at the 30-end of RNA backbone, or the combi-
nation of 40-thiolation with 20-O-alkyl modification [44,45].
The basic requirement of successful modifications is
enhancing siRNA serum stability without negative effects on
its gene silencing activity. Indeed, some kinds of modification
can compromise efficiency. For example, boranophosphonate
modification at the center of the antisense strand enhances
the resistance of siRNA to nucleases, although it reduces RNAi
activity [46]. In addition, the metabolites of these modifica-
tions should also be addressed as a safety issue.4.2. Lipid-based vectors for anti-cancer siRNA delivery
Lipofectamine 2000 is a kind of cationic lipid formulation that
is widely used for in vitro plasmid DNA or siRNA transfection.
Lipofectamine 2000 or the recently developed lipofectamine
RNAimax are effective siRNA transfection agents in vitro
which can improve the transfection efficacy by thousands of
times [47]. The transfectionmechanism of liposomes involves
electrostatic interactions between negatively charged nucleic
acids and positively charged lipids. When mixed together,
they spontaneously form lipoplexes [48e50].
Because the surface charge of all biological membranes is
negative, electronegative or neutral liposomes are more
biocompatible than cationic liposomes and have superior
pharmacokinetics in general. DOPC (1,2-dioleoylsn-glycero-3-
phosphatidylcholine) is a kind of neutral lipid which has been
used to improve siRNA entrapment efficiency. In 2005, Landen
et al. developed the oncoprotein EphA2 targeting DOPC-
encapsulated siRNA liposome, which was highly effective in
reducing EphA2 expression 48 h after administration of a
single dose in an orthotopic model of ovarian carcinoma [51].
Currently, the EphA2 targeting DOPC-encapsulated siRNA
liposome (siRNA-EphA2-DOPC) is in a Phase I clinical trial
initiated by the M.D. Anderson Cancer Center. Since electro-
negative or neutral liposomes are not easily endocytosed by
cells, cationic liposomes are still the best choice. For example,
dioleoyl-phosphatidylethanol-amine and 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP) is cationic lipids
which form cationic liposomes with negatively charged siRNA
[52]. Sorensen et al. used cationic DOTAP liposomes to deliver
siTNF-a, and the lethal reaction to LPS injection in a mouse
model of sepsis was suppressed [53]. To maintain an overall
positive surface charge for adsorption through the cell mem-
brane and to reduce the possible clearance caused by positive
charge, the N/P (nitrogen to phosphate) ratio usual ranges
from 2 to 3 [47].
Coating liposomes with lipid-anchored PEG can reduce
particle size [54], prevent aggregation during storage, increase
circulatory half-life and reduce uptake by the reticuloendo-
thelial system (RES) such as red blood cells and macrophages
[54]. But using PEG is not always advantageous, as the steric
effect and charge effect of PEG block the interaction between
the liposome and the endosomal membrane and prevent the
liposome from escaping the endosome. Many studies have
been performed to improve the efficacy of PEGylated nano-
particles, including rationally designed PEG length and den-
sity or incorporation of pH-sensitive bonds linking PEG to the
liposome. How to achieve the best outcome with modulation
of PEG length and density is still controversial, but pH-
sensitive modified PEG with ionic interactions, such as the
HEMAehistidineemethacrylic acid modified PEG liposome,
has been shown to be effective. At neutral pH, the PEG
copolymer has a net negative charge, whereas the liposomal
core, which consists of DOPE and cholesterol, has a net posi-
tive charge. In the endosome, imidazole and methacrylic acid
residues become protonated, and the net charge of the PEG
becomes positive, which results in PEG release and positively
charged liposomal membrane exposure, after which the
liposome can fusewith the endosome and escape successfully
[55]. Atu027 is a lipoplexed siRNA drug targeting protein
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lymph node metastases in mouse models of prostate and
pancreatic cancer and various mouse models of lung metas-
tasis [56]. Silence Therapeutics (London, UK) is performing a
Phase I trial of Atu027. Preliminary result revealed that Atu027
was well tolerated up to a dose of 0.18 mg/kg and was not
associated with dose-dependent toxicity [57].
The most famous lipid based vectors that used for clinical
trials are the SNALPs (stable nucleic acid-lipid particles).
SNALPs are a kind of lipid nanoparticles which encapsulate
siRNA and deliver it to the target cells. SNALPs aremicroscopic
particles approximately 120 nm in diameter. They have been
used to deliver siRNAs therapeutically to mammals in vivo. In
SNALPs, the siRNA is surrounded by a lipid bilayer containing
a mixture of cationic and fusogenic lipids, coated with
diffusible polyethylene glycol [58]. With enhanced perme-
ability and retention due to prolonged circulation time in the
blood, SNALPs are highly bioavailable, which leads to the
accumulation of SNALPs at the sites of vascular leakage,
especially at cancer growth sites. After accumulation, SNALPs
are easily endocytosed by cancer cells and deliver siRNA into
cells successfully. SNALPs have been used for the treatment of
many diseases, including hepatitis B viral infection, dyslipi-
demia and Ebola (Zaire) [20]. Judge et al. have successfully
demonstrated a 75% reduction in subcutaneous tumor size
with SNALP-siPlk1 treatment [59]. Tekmira Pharmaceuticals
Corporation (Burnaby, BC, Canada) initiated a Phase I trial of
SNALP-encapsulated siRNA targeting Plk1 (TKM080301) in
adult patients with solid tumors or lymphomas in December
2010. Alnylam Pharmaceuticals (Cambridge, MA, USA) has
developed the first dual-targeted siRNA drug, SNALP-
formulated siRNAs targeting vascular endothelial growth
factor (VEGF) and KSP in ALN-VSP02. A Phase I trial for the
treatment of advanced solid tumors with liver involvement
was initiated in April 2009. Interim data from the initial 28
patients in the first six-dose cohorts demonstrated that ALN-
VSP02 was generally well tolerated at the highest dose
(1.25 mg/kg) [60].
Another lipid-like delivery system is lipidoid nanoparticles,
which are comprised of cholesterol and PEG-modified lipids
specific for siRNA delivery [60]. To improve SNALP-mediated
delivery, Akinc et al. developed a new chemical method for
the rapid synthesis of a large library of lipidoids and tested
their efficacy in siRNA delivery [61]. One of the most potential
lipidoid drugs was the lipidoid-based siRNA formulation
98N12-5, which led to a 75e90% reduction in ApoB or FVII
factor expression in hepatocytes in non-human primates and
mice [61].
4.3. Polymer-mediated anti-cancer siRNA delivery
systems
Polymer-mediated delivery systems, usually called polymeric
nanoparticles, are solid, biodegradable, colloidal systems
which have been widely studied as drug vesicles [62]. Ac-
cording to the material used, polymer-mediated delivery
systems can be divided into two categories: water-soluble
cationic polymers and polymer nanoparticles. For anti-
cancer siRNA delivery, water-soluble cationic polymers
mainly include cyclodextrin or polyethyleneimine (PEI), whilepolymer nanoparticles are usually based on polycaprolactone
(PCL), poly(D,L-lactide) (PLA) and poly(D,L-lactide-co-glycolide)
(PLGA) [63].
Cyclodextrin is the most promising candidate natural
polymer for siRNA delivery. It was first introduced for the
delivery of plasmid DNA in 1999 and later reoptimized for
siRNA delivery. Less than a decade later, cyclodextrin polymer
(CDP)-based nanoparticles were moved into clinical trials for
siRNA delivery. Cyclodextrin polymer nanoparticle was the
first targeted siRNA delivery system which entered clinical
trials for cancer treatment [64]. Cyclodextrin polymers are
polycationic oligomers synthesized by a step-growth poly-
merization between diamine-bearing cyclodextrin monomers
and dimethyl suberimidate, yielding oligomers with amidine
functional groups [65]. In cyclodextrin polymer-mediated
siRNA delivery systems, adamantaneePEG (ADePEG) and
adamantaneePEGetransferrin (ADePEGeTf) are usually used
to improve delivery efficacy in vivo [66,67]. For AD-PEG-Tf,
adamantane can stabilize the cyclodextrin core by form a
stable inclusion complex. PEG shielding can reduce blood
clearance by protecting particles from serum proteins while
decreasing cellular uptake and silencing efficacy. Conjugated
transferrin is a targeting component which can bind to the
transferrin receptor CD71 [68]. Calando Pharmaceuticals
(Pasadena, CA, USA) have developed CALLA-01, which targets
the M2 subunit of ribonucleotide reductase (R2) to inhibit
tumor growth [3].
Polyethylenimine (PEI) has been used successfully for
nucleic acid delivery under both in vitro and in vivo conditions
[69-71]. However, high molecular weight PEIs provide high
transfection efficiency but also have high toxicity, while low
molecular weight PEIs are more biocompatible but are much
less efficient. Navarro et al. reported a type of micelle-like
nanoparticle (MNP), based on the combination of a covalent
conjugate between a phospholipid and low molecular weight
PEI (1.8 kDa) with PEG-stabilized liposomes as the outer layers
[72]. The MNP complexes had a size of ~200 nm and a neutral
surface charge after the addition of a PEG-lipid coating, which
protected the loaded siRNA against enzymatic digestion and
enhanced the cellular uptake of the siRNA payload. MNPs
have been shown to have the capacity for siRNA delivery and
gene silencingwith improved biocompatibility properties. The
MNP delivery system was further utilized in silencing P-gp to
overcome doxorubicin resistance in MCF-7 human breast
cancer cells. The presence of P-gp on the surface of resistant
cells decreased after treating cells with MNP-loaded siRNA
targeting MDR-1, which effectively inhibited the drug efflux
activity. The amount of doxorubicin inside MDR-1-treated
cells doubled compared control cells, and led to a two-fold
decreased in cell viability after drug treatment for different
intervals, similar to values in sensitive cells [73].
Polycaprolactone (PCL) is usually used for polymeric
micelle siRNA drug delivery systems. Sun et al. described the
production of self-assembledmicellar nanoparticles (MNPs) of
a triblock copolymer, monomethoxy poly(ethylene glycol)-
block-poly(ε-caprolactone)-blockpoly(2-aminoethyl ethylene
phosphate) (PPEEA) (mPEG-b-PCL-b-PPEEA) (Fig. 2) [74]. In this
system, the hydrophilic phosphoester PPEEA, which is
considered biocompatible and biodegradable, served as the
siRNA binding site, and another hydrophilic block PEG
Fig. 2 e Polymeric micelle siRNA drug delivery systems.
mPEG-b-PCL-b-PPEEA is a well-defined triblock copolymer,
consisting of a monomethoxy poly(ethylene glycol) (mPEG)
block, a poly(ε-caprolactone) (PCL) block and a cationic
poly(2-aminoethyl ethylene phosphate) (PPEEA) block
which can self-assemble into cationic micellar
nanoparticles to be loaded with siRNA.
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nanoparticles from clearance in the circulation. The siRNA-
loaded nanoparticles, known as Micelleplex, can be effec-
tively internalized and subsequently release siRNA into cells,
resulting in significant gene knockdown activity, which was
demonstrated by delivering two siRNAs targeting green fluo-
rescence protein (GFP) that effectively silenced GFP expression
in 40e70% of GFP-expressing HEK293 cells [74]. mPEG-b-PCL-b-
PPEEA has also been used for acid ceramidase (AC), HIF1 and
CDK4 siRNA delivery to successfully treat different kinds of
cancer in the mouse [75e77].
Poly(D,L-lactide) (PLA) and poly(D,L-lactide-co-glycolide)
(PLGA) have also demonstrated the potential for sustained
nucleic acid delivery [78e80]. In 2009, Saltzman and co-
workers reported that PLGA nanoparticles can be densely
loaded with siRNA in the presence of spermidine and, when
applied topically to the vaginal mucosa, lead to efficient and
sustained gene silencing [81]. Yang et al. reported a cationicFig. 3 e Cationic lipid assisted polymeric nanoparticle systems.
Chol: N,N-bis(2-hydroxyethyl)-N-methyl-N-(2-cholesteryloxycar
water phase and oil phase, respectively. Copyright 2011, Elsevilipid assisted polymeric nanoparticle system with stealthy
property for efficient siRNA encapsulation and delivery, which
was fabricated with poly(ethylene glycol)-b-poly(D,L-lactide),
siRNA and a cationic lipid, using a double emulsion-solvent
evaporation technique (Fig. 3). By incorporation of the
cationic lipid, the encapsulation efficiency of siRNA into the
nanoparticles was greater than 90%. The siRNA loading
weight ratio was up to 4.47%, while the diameter of the
nanoparticles was around 170e200 nm. The siRNA retained its
integrity within the nanoparticles, which were effectively
internalized by cancer cells and escaped from the endosome,
resulting in significant gene silencing. Systemic delivery of
specific siRNA by nanoparticles significantly inhibited lucif-
erase expression in an orthotopic murine liver cancer model
and suppressed tumor growth in a MDA-MB-435s murine
xenograft model, suggesting its therapeutic promise in dis-
ease treatment [82]. Using the same cationic lipid-assisted
polymeric nanoparticle system, Shen et al. delivered GATA2
siRNA to non-small-cell lung carcinoma (NSCLC) harboring
oncogenic KRAS mutations and successfully inhibited tumor
growth in mouse model [83].4.4. Conjugate siRNA delivery systems for cancer
therapy
Directly conjugation of delivery materials to siRNA has been
shown to be a promising system for siRNA delivery. The
most common conjugate materials are small drug mole-
cules, aptamers, lipids, peptides, proteins and polymers [84].
This system has a quite obvious advantage for cancer ther-
apeutic clinical use, since the system is simple and well-
defined.
Lipophile-siRNA conjugates, whichwere the first conjugate
delivery systems to show efficacy in vivo, consist of siRNA
conjugated to cholesterol [85] and other lipophilic molecules
[24]. Cholesterol was conjugated to the 30-terminus of the
sense strand of siRNA via a pyrrolidone linkage. Cholesterol
not only increased the transfection efficacy of siRNA in vitromPEG-PLA: poly(ethylene glycol)-b-poly(d,l-lactide); BHEM-
bonyl aminoethyl) ammonium bromide; W and O represent
er B. V.
Fig. 4 e Exosome-mediated siRNA targeted delivery.
Exosome is a kind of extracellular membrane vesicles
(EMV), which can be decorated with targeting ligand and
loaded with siRNA. As EMV, siRNA-loaded exosome can be
uptake by cells quite efficiently. Copyright 2012, Dimitrov,
Cummins, Mayko and Portfors.
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[85]. To further optimize cholesterol-siRNA, high density li-
poprotein (HDL) was bound which increased gene silencing
efficacy by 8e15 fold in vivo [24].
CPPs (cell-penetrating peptides) are another conjugate
material used for siRNA transfection efficacy improvement. A
well-known CPP is the TAT trans-activator protein from
human immunodeficiency virus type-1 (HIV-1). TAT has been
conjugated to the 30-terminus of the antisense strand of an
siRNA using a heterobifunctional cross-linker (HBFC), i.e.
sulfosuccinimidyl-4-(p-maleimidophenyl) butyrate [86]. The
TAT-siRNA conjugate demonstrated a dramatic improvement
in the intracellular delivery of siRNA. However, CPP-siRNA
conjugates may exhibit cytotoxicity caused by cell mem-
brane perturbation or immunogenicity [87].
A targeted delivery system is always the dream for anti-
cancer drug development. For siRNA targeted delivery, pep-
tides, antibodies and aptamers have been used. For the
receptor-ligand mediated delivery of siRNA, the carboxylic
acid group of a peptide mimetic of IGF1, D-(Cys-Ser-Lys-Cys),
was activated and conjugated to an amine group of the 50-
sense strandof siRNA.This strategy resulted in 60%expression
reduction of IRS1 (insulin receptor substrate 1), which was
similar to the chol-siRNA conjugate [88]. Antibody-mediated
targeted drug delivery systems have attracted much atten-
tion due to their superior stability and high specificity. A
monoclonal antibody targeting the transferrin receptor at the
bloodebrain barrier was directly conjugated to siRNA via a
biotin-streptavidin linkage. The intravenous administration of
the antibody-siRNA conjugate led to the efficient suppression
of reporter gene expression in a rat model bearing intracrani-
ally transplanted brain tumors [89]. Aptamers, such as the
prostate-specificmembrane antigen (PSMA) targetedaptamer,
are modified oligonucleotides with selective affinities toward
specific proteins. When conjugated to siRNA using streptavi-
din via streptavidin-biotin interactions, PSMA-targeted
aptamers have successfully facilitated siRNA uptake by
PSMA-overexpressing cells without using transfection agents
[90]. Regarding these promising conjugate delivery systems,
the two most advanced conjugate systems, i.e. DPCs and Gal-
NAc conjugates, are already in clinical trials [40].
4.5. Other possible anti-cancer siRNA delivery systems
Apart from the previously studied siRNA delivery systems
described above, there are somenewsiRNAdelivery strategies,
such as exosome-mediated siRNA delivery systems, oligonu-
cleotide nanoparticles and RNAi-microsponges. Although
these delivery platforms are not verywell-developed, they still
show great potential in siRNA delivery.
Exosomes are small vesicles (40~100 nm) released from
cells upon the fusion of a multivesicular body (MVB) con-
taining intraluminal vesicles with the plasma membrane
[91]. They have been shown to be natural carriers of coding
and non-coding RNA, including miRNA, with the ability to
induce de novo transcriptional and translational changes in
target cells [92e96]. The ability of exosomes to transfer
mRNA and miRNA between cells and subsequently to
mediate changes in gene expression in recipient cells,
together with their high abundance in most body fluids,highlights their potential as delivery vehicles for RNAi. El-
Andaloussi et al. were the first to harness this potential
and provide the first proof of concept for the biotechnological
exploitation of exosomes [97]. They specifically targeted
dendritic cell-derived exosomes to the brain by displaying a
rabies virus glycoprotein (RVG)ederived peptide, and then
loaded them with siRNA for delivery both in vitro and in vivo
(Fig. 4). By using this method, they demonstrated specific
delivery of siRNA to neurons in the brain following systemic
delivery in mice, with up to 60% RNA and protein knockdown
predominantly in the midbrain, cortex and striatum, and
little homing of the exosome cargo to the liver. In addition to
efficient and specific delivery of siRNA, these exosomes
produced little or no toxicity or immunogenicity, even after
repeated i.v. administration [98].
Oligonucleotide nanoparticles (ONPs) are composed of
complementary DNA fragments designed to hybridize into
predefined three-dimensional structures (Fig. 5) [40]. A pre-
viously describedmethod [99] of constructing DNA tetrahedra
was adapted by incorporating single-stranded overhangs on
each edge [32]. siRNAs were modified by extension of the 30-
sense strands with DNA overhangs that enabled hybridiza-
tion to the edges of the tetrahedra. By using unique overhang
sequences, six siRNA strands could be attached to each par-
ticle, each in a specified position. The resulting nanoparticles
had a hydrodynamic diameter of about 29 nm [40]. Oligonu-
cleotide nanoparticles modified with folate ligands were used
to study the minimum number of targeting ligands required
for delivery and to probe the optimal arrangement of these
ligands. A minimum of three folate ligands was required to
achieve significant gene silencing, yet incorporation of more
than three ligands did not greatly improve silencing effi-
ciency. Furthermore, the positioning of the three ligands was
critical: ONPs with three ligands arranged to maximize local
density (all three ligands arranged around one side or one
vertex) showed efficient silencing, whereas those with li-
gands distant from one another had lower silencing activity
[32]. At a dose of 2.5 mg/kg, folateeONPs silenced luciferase
expression in the tumor by ~60% without significant
immunostimulation.5. Conclusions and future prospects
As one of the most promising drugs for cancer treatment,
siRNA has great advantages, such as excellent safety, high
Fig. 5 e Self-assembly of oligonucleotide nanoparticles. DNA tetrahedra carrying six siRNAs were synthesized in a single
step through hybridization of complementary strands. Positioning of each siRNA on the surface of the tetrahedron could be
controlled by using unique sequences in each of the siRNA 3′ overhangs. Copyright 2013, Macmillan Publishers.
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the delivery problems of siRNA, many delivery systems have
been developed. These highly effective delivery systems are
quite different in terms of structure, size and chemistry, but
there are still some guidelines regarding the characteristics of
optimal delivery systems. Nanoparticulate delivery systems
should have a particle size of about 20e200 nm, i.e. be large
enough to avoid renal filtration but small enough to evade
phagocytic clearance. PEG as the shielding agent has proven to
be valuable in preventing non-specific interactions and
avoiding immune recognition in the circulation [40]. Chemical
modifications, such as 20-O-methyl substitutions, are neces-
sary to minimize non-specific effects and avoid nuclease
digestion. In addition, endogenous or exogenous targeting li-
gands are also often beneficial for siRNA uptake by cancer
cells. Although a number of reports have demonstrated the
great potential of siRNA in cancer treatment, challenges
remain in bringing the full potential of siRNA to the clinic, and
most siRNA drug delivery systems are still in preclinical
studies. In recent years, siRNA drug development has expe-
rienced highs and lows. The attitude of big pharmaceutical
companies to RNAi drugs has also become over-optimistic. In
summary, a good delivery system is the key to siRNA drug
development. Once research into siRNA drug delivery systems
makes a significant breakthrough, siRNA will occupy a strong
position in the drug market, especially the anti-cancer drug
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